• Partnership seeks to improve Cryopreservation for Cell Therapies

News & Views

Partnership seeks to improve Cryopreservation for Cell Therapies

Aug 01 2023

Cell therapy and regenerative medicine solutions provider Cyto-care.eu GmbH (Vienna) has signed an agreement with cell-based therapy and viral vectors CDMO SCTbio, to improve the quality of cryopreservation for cell therapy development in Europe, through addressing the critical need for efficient collection, cryopreservation, quality control and logistics capabilities of leukapheresis materials which support various aspects of the cell therapy workflow.

Cell collection through leukapheresis procedure is a key enabling step for manufacturing advanced cell therapies products (ATMPs), made from human cells or tissue that are life-saving therapies. The quantity and quality of collected immune cells, like T cells and natural killer cells used for cell therapies, directly impact the potency, safety and efficacy of the final therapeutic product. As such, efficient cryopreservation and logistics of these leukapheresis materials are critical to ensure the preservation of cell viability and functionality during transportation and storage.

Ludek Sojka, CEO of Czech Republic-based SCTbio, stated, “We are thrilled to combine both forces and expertise with Cyto-care.eu, a European leader in producing quality blood-based products from leukapheresis, through this strategic partnership. As the cell and gene therapy field continues to advance, the demand for leukapheresis materials is expected to increase. Clinical trials and commercial production of these therapies require a consistent and reliable supply of high-quality blood-derived products to meet patient needs.”

“Through rigorous analysis and in-depth discussions with the experts of the field, the Needle-to-Freezing time has been identified as a crucial factor for success for the development and manufacturing of ATMPs,” said Klaus Fischer, Cyto-care.eu’s Managing Director. “Through this collaboration with SCTbio, we can ensure that our leukapheresis products from patients and from donors continue to meet the high-quality standards of our customers’ requirements.”

More information online


Digital Edition

Lab Asia 31.1 - February 2024

February 2024

In This Edition Chromatography Articles - Comparing techniques for flow rate measurement in Liquid Chromatography Mass Spectrometry & Spectroscopy Articles - APGC: A Better Future with...

View all digital editions

Events

Asia Pharma Expo/Asia Lab Expo

Feb 29 2024 Dhaka, Bangladesh

Nepal Lab

Feb 29 2024 Kathmandu, Nepal

IFPAC 2024

Mar 03 2024 Bethesda, MA, USA

SIAF Guangzhou

Mar 04 2024 Guanghzou, China

China Lab 2024

Mar 05 2024 Guangzhou, China

View all events